http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009117545-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78c49e5732cca4051fc1048035d7e01a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c98284dbc1069638ae199f49c68c5945 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9b958d3dc55d2a415b7aed186443902 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-002 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-67 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
| filingDate | 2005-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f05a64e141b9a675595b7c6b67604e40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa230374f6b153f1c26bef5e72dff0c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d3f684f9268c23cc8bedec82f9dbc71 |
| publicationDate | 2009-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009117545-A1 |
| titleOfInvention | Glycine riboswitches, methods for their use, and compositions for use with glycine riboswitches Cross-Reference to Related Applications |
| abstract | It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013310458-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110636868-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018034843-A1 |
| priorityDate | 2004-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1300.